The Prevention Paradox

• by Nathan Radcliffe, MD

• September 1, 2026

Cutaneous laser treatment of port-wine stains and its impact on ocular manifestations in Sturge–Weber syndrome

• by Susan Darby Keith, Grace Herrick, Ashton Arlen, Halrleen K. Multani, Kelly Frasier, Kathryn Dempsey, Paul McDaniel

• June 30, 2026

Perspectives on Medicare’s Proposed iDose TR Coverage Policy

In May 2026, 5 Medicare Administrative Contractors released proposed Local Coverage Determinations (LCDs) addressing Medicare reimbursement for anterior-segment intraocular nonbiodegradable drug-eluting systems, a category that currently includes only the travoprost intracameral implant iDose TR (Glaukos). Many glaucoma specialists believe the proposed LCDs do not reflect contemporary glaucoma practice or the clinical rationale underlying sustained drug-delivery therapies. Glaucoma Physician spoke with several leading surgeons about the proposed LCDs, the reasons for their concerns, and the changes they believe would better reflect contemporary glaucoma practice.

• by Steven R. Sarkisian, Jr., MD, Inder Paul Singh, MD, Savak “Sev” Teymoorian, MD, MBA, Manjool Shah, MD, Christine Funke, MD, Philip S. Garza, MD, MSc

• September 1, 2026

• 10 min

Optimizing MIGS for Practice and Center Success

The key is execution, understanding the clinical landscape, controlling device cost, engineering the intraoperative workflow, and scheduling/staffing with intention.

• by Mitchell C. Shultz, MD

• July 1, 2026

• 9 min